MAiD & Mature Minors - A Panel Discussion
Saturday, May 4, 2024 |
11:30 AM - 12:30 PM |
Speaker(s)
Michelle Mullen and Adam Rapoport
Session Details
At the end of this session, participants will be able to:
- Articulate the key arguments and considerations for and against this expansion, and understand the legal and ethical implications
- Discuss the potential extension of MAiD to mature minors, exploring the ethical, medical, and practical complexities of this decision and its potential impact on healthcare policies and practices
Speaker
Michelle Mullen
CHEO
Panelist
Biography
Head, Bioethics Service CHEO
Associate Professor, Department of Paediatrics University of Ottawa
Michelle Mullen is an Associate Professor of Paediatrics, Bioethicist at the Children’s Hospital of Eastern Ontario (CHEO) and founding member of the palliative care team at CHEO. Michelle has broad health training with degrees in Human Physiology and Psychology, Health Policy and is the first doctoral graduate of University of Toronto’s joint collaborative program in Bioethics. Her scholarly publications span bench and clinical research, health policy analyses and Bioethics.
Michelle is interested in the dialectic between bedside, institutional and social considerations in bioethics analyses with a particular concern with attending to unheard voices and mitigating vulnerability and marginalization; seeing social justice as a fundamental concern in much bioethics deliberation. She brings these lenses to bear on bioethics in myriad contexts: children and youth, Indigenous health, newcomer/refugee health experience, organ donation and paediatric/youth palliative care.
I have an affiliation (financial or otherwise) with any for-profit or not-for-profit organizations.
- Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: OCREB (board ethicist, honorarium)
I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medications).
Associate Professor, Department of Paediatrics University of Ottawa
Michelle Mullen is an Associate Professor of Paediatrics, Bioethicist at the Children’s Hospital of Eastern Ontario (CHEO) and founding member of the palliative care team at CHEO. Michelle has broad health training with degrees in Human Physiology and Psychology, Health Policy and is the first doctoral graduate of University of Toronto’s joint collaborative program in Bioethics. Her scholarly publications span bench and clinical research, health policy analyses and Bioethics.
Michelle is interested in the dialectic between bedside, institutional and social considerations in bioethics analyses with a particular concern with attending to unheard voices and mitigating vulnerability and marginalization; seeing social justice as a fundamental concern in much bioethics deliberation. She brings these lenses to bear on bioethics in myriad contexts: children and youth, Indigenous health, newcomer/refugee health experience, organ donation and paediatric/youth palliative care.
I have an affiliation (financial or otherwise) with any for-profit or not-for-profit organizations.
- Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: OCREB (board ethicist, honorarium)
I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medications).
Dr. Adam Rapoport
Physician
Hospital For Sick Children
Panelist
Biography
Medical Director, Emily’s House Children’s Hospice
Associate Professor, Departments of Paediatrics and Family & Community Medicine, University of Toronto
Adam Rapoport is a general pediatrician with a Masters in bioethics. In 2009, Adam joined the Temmy Latner Centre for Palliative Care at Mount Sinai Hospital as their pediatric consultant. In July 2011 he became the first Medical Director of the Paediatric Advanced Care Team (PACT), the palliative care service at SickKids. PACT provides both inpatient and outpatient palliative care to children with serious illnesses, and their families. In 2013 Adam became Medical Director at Toronto’s first pediatric residential hospice – Emily’s House. Adam has co-chaired Ontario’s Provincial Pediatric Palliative Care Steering Committee since 2018 and he was appointed by Ontario Health to lead the development of a provincial model of pediatric palliative care in 2022. He has more than 50 peer-reviewed publications and was co-editor of the Oxford Textbook of Palliative Care for Children (3rd ed). Adam’s academic work focuses on the intersection of his 3 primary interests: pediatrics, palliative care and ethics.
I do not have an affiliation (financial or otherwise) with a for-profit or not-for-profit organization.
I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medications).
Associate Professor, Departments of Paediatrics and Family & Community Medicine, University of Toronto
Adam Rapoport is a general pediatrician with a Masters in bioethics. In 2009, Adam joined the Temmy Latner Centre for Palliative Care at Mount Sinai Hospital as their pediatric consultant. In July 2011 he became the first Medical Director of the Paediatric Advanced Care Team (PACT), the palliative care service at SickKids. PACT provides both inpatient and outpatient palliative care to children with serious illnesses, and their families. In 2013 Adam became Medical Director at Toronto’s first pediatric residential hospice – Emily’s House. Adam has co-chaired Ontario’s Provincial Pediatric Palliative Care Steering Committee since 2018 and he was appointed by Ontario Health to lead the development of a provincial model of pediatric palliative care in 2022. He has more than 50 peer-reviewed publications and was co-editor of the Oxford Textbook of Palliative Care for Children (3rd ed). Adam’s academic work focuses on the intersection of his 3 primary interests: pediatrics, palliative care and ethics.
I do not have an affiliation (financial or otherwise) with a for-profit or not-for-profit organization.
I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medications).